These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6797089)

  • 41. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1.
    Gachet C; Cazenave JP; Ohlmann P; Bouloux C; Defreyn G; Driot F; Maffrand JP
    Biochem Pharmacol; 1990 Dec; 40(12):2683-7. PubMed ID: 2175608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Binding of factor VIII/Willebrand to Bernard-Soulier and thrombasthenic platelets (author's transl)].
    Ruan C; Tobelem G; Caen JP
    Nouv Rev Fr Hematol (1978); 1981; 23(2):89-93. PubMed ID: 6794004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coagulation assays and platelet aggregation patterns in human, baboon, and canine blood.
    Feingold HM; Pivacek LE; Melaragno AJ; Valeri CR
    Am J Vet Res; 1986 Oct; 47(10):2197-9. PubMed ID: 3096173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of oral ticlopidine on arachidonic acid products in human platelets.
    Bruno JJ; Chang LF; McSpadden MM; Yang D
    Agents Actions Suppl; 1984; 15():76-87. PubMed ID: 6435408
    [No Abstract]   [Full Text] [Related]  

  • 45. 125I-fibrinogen binding to platelets in myeloproliferative disease.
    Mistry R; Cahill M; Chapman C; Wood JK; Barnett DB
    Thromb Haemost; 1991 Sep; 66(3):329-33. PubMed ID: 1746004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of vancomycin on platelets, plasma proteins and hepatitis B surface antigen.
    Coller BS; Lundberg WB; Gralnick HR
    Thromb Diath Haemorrh; 1975 Sep; 34(1):83-93. PubMed ID: 1188837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mechanism of platelet aggregation inhibition].
    Abiko Y; Ashida S
    Rinsho Byori; 1979; Suppl 40():169-80. PubMed ID: 233105
    [No Abstract]   [Full Text] [Related]  

  • 48. Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.
    Randi ML; Mares M; Fabris F; Tison T; Barbone E; Girolami A
    Arzneimittelforschung; 1991 Apr; 41(4):414-6. PubMed ID: 1859515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.
    Cattaneo M; Winocour PD; Somers DA; Groves HM; Kinlough-Rathbone RL; Packham MA; Mustard JF
    Thromb Res; 1985 Jan; 37(1):29-43. PubMed ID: 3983900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production.
    Lagarde M; Ghazi I; Dechavanne M
    Prostaglandins Med; 1979 Jun; 2(6):433-9. PubMed ID: 399526
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Membrane receptors for fibrinogen and factor VIII and abnormalities of platelet function. A review.
    Di Minno G; Palladino M; Mattioli PL; Mancini M
    Haematologica; 1985; 70(4):354-7. PubMed ID: 3000900
    [No Abstract]   [Full Text] [Related]  

  • 52. Evans blue: a specific inhibitor of factor VIII-induced platelet agglutination.
    Kirby EP
    Thromb Diath Haemorrh; 1975 Dec; 34(3):770-9. PubMed ID: 1239827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease.
    Randi ML; Fabris F; Crociani ME; Battocchio F; Girolami A
    Arzneimittelforschung; 1985; 35(12):1847-9. PubMed ID: 4096744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease.
    Carrieri P; Orefice G; Fioretti A; Indaco A; Carfagna S
    J Int Med Res; 1984; 12(5):286-91. PubMed ID: 6500168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
    Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
    Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
    [No Abstract]   [Full Text] [Related]  

  • 56. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.
    Lecrubier C; Conard J; Horellou MH; Samama M
    Agents Actions; 1983 Feb; 13(1):77-80. PubMed ID: 6858789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of the active metabolite of ticlopidine from rat in vitro metabolites.
    Yoneda K; Iwamura R; Kishi H; Mizukami Y; Mogami K; Kobayashi S
    Br J Pharmacol; 2004 Jun; 142(3):551-7. PubMed ID: 15148251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Studies on the mechanism of ristocetin-induced platelet aggregation: binding of factor VIII to platelets.
    Schneider-Trip MD; Jenkins CS; Kahlé LH; Sturk A; ten Cate JW
    Br J Haematol; 1979 Sep; 43(1):99-112. PubMed ID: 508625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ticlopidine - an antiplatelet drug: effects in human volunteers.
    O'Brien JR; Etherington MD; Shuttleworth RD
    Thromb Res; 1978 Aug; 13(2):245-54. PubMed ID: 694843
    [No Abstract]   [Full Text] [Related]  

  • 60. Factor VIII and human platelet aggregation. IV. Effect of proteolytic enzymes on platelet aggregation by factor VIII.
    Vermylen J; Bottecchia D
    Br J Haematol; 1976 Oct; 34(2):331-40. PubMed ID: 135576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.